Lung Cancer
Lung Cancer Updates
Had my patient come in today, we may have had other options
FDA’s approval of trastuzumab deruxtecan is a game-changer for NSCLC patients with HER alterations.
Diminutio
Cancer as a full contact sport
The complexity of cancer care has long necessitated a team approach to planning cancer treatment.
Lung Cancer Updates
In progressive lung cancer second biopsies may be the norm now
Many years after their discovery, we finally have a new string of EGFR-TKI approvals for NSCLC.
From the Journals
Despite benefits, extended-interval pembro uptake remains low
It’s possible that low uptake could stem from clinicians’ doubts about switching to an extended-interval dose, given that the FDA’s approval was...
Conference Coverage
Weight gain linked to cancer survival in men and women
The finding underscores the need for nutritional support emphasized in 2020 ASCO guidelines.
News
FDA OKs selpercatinib for adults with RET-fusion+ solid tumors
In 2020, selpercatinib received accelerated approval for lung and thyroid RET-positive tumors.
Conference Coverage
High BMI linked to better survival for cancer patients treated with ICI, but for men only
The reasons behind the findings and implications for treatment are unknown, as is whether it applies to patients with specific cancers.
Conference Coverage
Sotorasib superior to docetaxel in KRAS G12C–mutated NSCLC
In its first randomized, phase 3 comparison trial, the first-in-class agent sotorasib held its own against the standard of care docetaxel.
Latest News
Atezolizumab doubles survival of NSCLC patients with poor performance status
Patients typically excluded from clinical trials because of age or comorbidities had better survival with atezolizumab than single-agent...
Conference Coverage
A farewell to arms? Drug approvals based on single-arm trials can be flawed
Objective responses, not time-dependent survival outcomes, should be endpoints for single-arm trials, with results only used for conditional...
Conference Coverage
Time to cancer diagnoses in U.S. averages 5 months
Diagnosis time varied significantly across tumor types, as well as within the same tumor type.